Generic Name and Formulations:
Cefazolin (as sodium) 500mg/vial, 1g/vial; pwd for IM or IV inj or IV infusion after reconstitution and dilution; sodium content 48mg/g cefazolin.
Various generic manufacturers
Indications for Cefazolin:
Susceptible bacterial infections including septicemia, respiratory, biliary or GU tract, skin and skin structure, bone and joint, endocarditis. Surgical prophylaxis.
Pneumococcal pneumonia: 500mg every 12 hours. Mild infections: 250–500mg every 8 hours; moderate to severe infections: 500mg–1g every 6–8 hours. Severe, life-threatening infections (eg, endocarditis, septicemia): 1–1.5g every 6 hours; max 12g/day. UTIs: 1g every 12 hours. Prophylaxis: see literature. Renal impairment (give initial loading dose): (CrCl 35–54mL/min): reduce dosing frequency to at least 8 hour intervals; (CrCl 11–34mL/min): reduce dose by 50%, give every 12 hours; (CrCl <10mL/min): reduce dose by 50%, give every 18–24 hours. Peritoneal dialysis: see literature.
<1 month: not recommended. ≥1 month: Mild to moderately severe infections: 25–50mg/kg per day in 3–4 divided doses. Severe infections: max 100mg/kg per day. Renal impairment (give initial loading dose): (CrCl 40–70mL/min): reduce dose by 40%; give every 12 hours; (CrCl 20–40mL/min): reduce dose by 75%, give every 12 hours; (CrCl 5–20mL/min): reduce dose by 90%, give every 24 hours.
Penicillin or other allergy. Renal impairment: reduce dose. GI disease (esp. colitis). Monitor PT in patients at risk (eg, renal or hepatic impairment, poor nutritional state, long term use, or anticoagulant therapy). Pregnancy (Cat.B). Nursing mothers.
Potentiated by probenecid. May cause false (+) Clinitest, Benedict's, or Fehling's soln.
GI upset, anaphylaxis, rash, pruritus, local reactions, blood dyscrasias, elevated liver enzymes.
Formerly known under the brand names Ancef, Kefzol.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|